One clinical study has demonstrated that a non-erythropoietic peptide engineered from EPO could have beneficial effects on metabolic parameters and neuropathic symptoms in adults with Type 2 diabetes [50]. The gene discussed is EPO; the disease is type 2 diabetes mellitus.